Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis

K V Ramana1*, Venkata BharatKumar Pinnelli2, Sabitha Kandi3, Asha G2, Jayashankar CA4, Bhanuprakash5, Raghavendra DS2, Sanjeev D rao1

1Department of Microbiology, Prathima Institute of Medical sciences, Karimnagar, India
2Department of Biochemistry, Vydhehi Institute of Medical sciences and Research center, Bengaluru, India
3Department of Biochemistry, Chalmeda Anandaraao Institute of Medical sciences, Karimnagar, India
4Department of General Medicine, Vydhehi Institute of Medical sciences and Research center, Bengaluru, India
5Department of Dermatology, Vydhehi Institute of Medical sciences and Research center, Bengaluru, India
*Corresponding author: ramana_20021@rediffmail.com

Received August 15, 2014; Revised October 14, 2014; Accepted October 19, 2014

Abstract  Sepsis is a potential clinical condition which is a consequence of infectious disease or a severe inflammatory reaction secondary to infection or injury. Sepsis in Greek means putrefaction or decay, correlating well with the multiple organ failure and severe shock resulting in death of the patient suffering from severe sepsis. Clinical management of sepsis requires prompt laboratory diagnosis and formulation of effective patient management strategies that may include antimicrobial chemotherapy in case of sepsis induced by infectious microbe. Although many laboratory biomarkers are available for the diagnosis of sepsis, only few markers have proven to be beneficial in differentiating infectious disease sepsis and sepsis of non-infectious origin. Of the available markers only few have prognostic value. We in this review discuss the utility of a novel and emerging sepsis marker, the presepsin which has a better diagnostic and prognostic value, and has been effective in predicting the survival of the sepsis patients.

Keywords: presepsin, sepsis marker, management of sepsis


1. Introduction

Sepsis and septic shock are among the most important medical emergencies throughout the world. Advancement in the life support technologies have proven to be insufficient in reducing the mortality and morbidity arising from severe sepsis. In the era of multi-drug resistance, it becomes imperative that such cases should be diagnosed at the earliest and appropriate treatment and management measures should be initiated for better patient outcome/care [1]. Sepsis is defined as the two fold increase in inflammatory indicators. Some of the biomarkers currently available include C-reactive protein (CRP), procalcitonin (PCT), Interleukin-6 (IL-6), Plasma transforming growth factor-b1, Pro-vasopressin, pro-adrenomedullin (proADM), pro-atrial natriuretic peptide and myeloid cells expressing triggering receptor-1 (TREM-1), soluble urokinase-like plasminogen receptor (suPAR) [2-8]. Among the available biomarkers of sepsis, the CRP is still routinely used as a sepsis indicator in neonates [9]. Millions of deaths are reported due to sepsis throughout the world including both developed and developing nations [10]. Sepsis has been attributed to occur in 1-2% of hospitalized patients including those who are undergoing treatment in intensive care units (ICU) [11]. Among the many biomarkers which have been evaluated for their prognostic significance only PCT was found useful until recently [12]. Although the available biomarkers of sepsis have proven to be useful, the drawbacks include their elevated activities during non septic conditions like trauma, surgery, myocardial infarction and other conditions like systemic inflammatory response syndrome (SIRS), and immune response during septic conditions. Considering the fact that sepsis due to infection is microbiologically confirmed only in 30% of the cases, it is inevitable that there is need for other indicators of sepsis [13].

2. Presepsin: Soluble Subtype of CD14 (SCD14-ST)

Some of the biomarkers currently available have proven to be having less prognostic value and cannot be useful for predicting mortality [14]. Research in this direction has paved the way for identification of CD14, a glycopeptides expressed on macrophages and monocytes, which serves as a receptor for lipopolysaccharide-lipopolysaccharide
binding protein (LPS-LPB) of microorganisms as a potential biomarker. CD14 is a 55-kDa glycosyl phosphatidyl inositol-anchored protein lacking a cytoplasmic domain. CD14 is expressed on most innate immune response cells and exists either in an anchored membrane form (mCD14) or in a circulating soluble form (sCD14). The latter is a 43-53 kD glycoprotein that derives from either protease-mediated membrane CD14 shedding or liver synthesis as a type II acute-phase reactant. During inflammation, plasma protease activity generates CD14 fragments (Figure 1).

Figure 1. Mechanism of presepsin synthesis (acquired from medesa тестуеме.cz/Data/.../Presepsin/PF_Folder_SEPSIS_0605_II.pdf)

The SCD14-ST, a soluble CD14 subtype, a 13 kDa truncated N terminal fragment of 64 aminoacid residues is called as presepsin. This has been found to activate proinflammatory cascade on encountering microorganisms. It has been noted that plasma protein activity results in the production of SCD14 fragments. Among the fragments the SCD14 –ST fragment is recognised as a sepsis marker [15,16].

3. Current Research on Utility of Presepsin

Previous studies have evaluated the activities of SCD14-ST among healthy, mild sepsis, severe sepsis and systemic inflammatory response syndrome (SIRS) patients. Studies on the activities of presepsin in adults, neonates and post-mortem cases have highlighted the utility of presepsin as an efficient biomarker in the prognosis of sepsis when compared to others [17,18,19,20]. These studies have found that although PCT has a better diagnostic value, presepsin was instrumental in knowing the survival chances of the patient from higher mean presepsin activities in non-survivors as compared to survivors. A study published recently has compared the utility of both presepsin and pro-calcitonin in sepsis patients. This study had included 21 patients undergoing treatment at the critical care unit in a hospital in Italy. Results of this study have revealed that activities of both presepsin and PCT were lower among healthy individuals as compared to sepsis and severe sepsis patients \( (p<0.001) \). Results of the study have also confirmed the ability of both markers to differentiate between severe sepsis and systemic inflammatory response syndrome (SIRS). The study has also confirmed that when evaluating the treatment response, the presepsin was considerably superior over PCT in assessing the real condition of the patient [21]. The activities of presepsin in the diagnosis of bacteraemia among patients with systemic inflammatory response syndrome (SIRS) and non-SIRS was studied recently and found that presepsin levels were higher among patients with SIRS and bacteraemia when compared to non-SRIS patients with bacteraemia. This study has also noted that increased activities of presepsin \((>720 \text{ pg/mL})\) correlated well with mortality [22]. A study recently has compared the activities of PCT, presepsin and interleukin-6 (IL-6) for diagnosing bacterial and non-bacterial infectious disease related sepsis. The results of the study showed that at a cut-off of 600 pg/mL of presepsin, has been found useful in predicting bacterial and non-bacterial induced sepsis. This study has also revealed that presepsin (91.9%) was more sensitive than blood culture (35.4%) in diagnosing sepsis [23]. In a recent prospective observational study performed by Filippo Mearelli et al. among SIRS patients attending emergency care department evaluated the activities of presepsin, PCT, pro-adrenomedullin (proADM), fibrin degradation products and lactate. Results of this study have revealed higher levels of PCT, proADM and presepsin among infectious disease sepsis patients as compared to no-infectious sepsis patients [24]. Tatjan Vodnik et al. in their recent study evaluated the performance of presepsin pre-operative diagnosis of abdominal sepsis and found that presepsin was significantly higher in severe sepsis \((1508.3\pm866.6 \text{ pg/mL})\) group when compared to healthy individuals \((258.7\pm92.53)\) and SIRS patients \((430.0\pm141.33 \text{ pg/mL})\) [25]. Diagnosis of sepsis is difficult in patients with burns since these patients suffer from altered post burn metabolic profile. Özlem Çakır Madenci et al. in a recent study have compared the activities of PCT, CRP, white blood cell...
count (WBC) and presepsin in burns patients. This study has measured the activities of biomarkers tested every six hours starting from admission. The diagnostic accuracy of the measured sepsis markers including presepsin (83.4%), PCT (84.7%), CRP (81.9%) and WBC (50.8%) was found to be variable [26]. A recent study from Korea that evaluated the activities of presepsin, PCT, interleukin 6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) for their utility in the diagnosis of sepsis has revealed that among the biomarkers tested presepsin activities significantly differed in infectious (1403.47 pg/mL) and non infectious (239.00 pg/mL) group highlighting the importance of presepsin in the diagnosis and prognosis of sepsis [27]. A multicenter prospective study conducted recently by Shigetsu Endo et al. has shown that presepsin activities correlated well with the severity of sepsis at presentation and during follow-up [28]. Presepsin activities were also measured among the major organ transplant patients for possible sepsis diagnosis and the study results revealed that activities of presepsin were significantly higher (3034.43±2880.791) among transplant patients which correlated well with blood cultures [29].

4. Conclusion and Future Perspectives

Severe Immunological response to microbial infection (commonly by bacteria and occasionally by fungi, viruses and parasites) presenting as a systemic illness which may lead to multiple organ dysfunctions is termed as sepsis. Sepsis may also be observed in cases of trauma, burns patients, transplant patients and chronic organ failures (kidney, lungs and liver). Sepsis is a result of heightened inflammatory response during an infection/injury. Emergency laboratory and clinical management of patients suffering from sepsis is required to reduce the resultant morbidity and mortality. Neonates, pregnant women, patients undergoing transplantations, burns patients and geriatric age group are more susceptible to severe sepsis. Many laboratory biomarkers either singly or in combination have been routinely used for the laboratory diagnosis of sepsis. Presepsin is a novel sepsis biomarker that has been available recently. Although only few studies have attempted to evaluate the usefulness of presepsin, the literature available thus far clearly impresses upon the fact that presepsin has a potential role not only as a diagnostic marker but is also efficient in knowing the prognosis and survival chances of the sepsis patients. Further research on large scale multi-centric and comparative studies (with other available and newer biomarkers) in different geographical areas and patient groups is required to confirm the utility of presepsin as a potential sepsis biomarker.

References


